JP2014518252A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518252A5 JP2014518252A5 JP2014517915A JP2014517915A JP2014518252A5 JP 2014518252 A5 JP2014518252 A5 JP 2014518252A5 JP 2014517915 A JP2014517915 A JP 2014517915A JP 2014517915 A JP2014517915 A JP 2014517915A JP 2014518252 A5 JP2014518252 A5 JP 2014518252A5
- Authority
- JP
- Japan
- Prior art keywords
- cough
- condition
- respiratory
- oral composition
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010011224 Cough Diseases 0.000 claims 48
- 239000000203 mixture Substances 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 230000000241 respiratory effect Effects 0.000 claims 9
- 230000000954 anitussive effect Effects 0.000 claims 8
- 208000024891 symptom Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 206010061218 Inflammation Diseases 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- 206010060954 Abdominal Hernia Diseases 0.000 claims 3
- 206010013952 Dysphonia Diseases 0.000 claims 3
- 206010019909 Hernia Diseases 0.000 claims 3
- 208000010473 Hoarseness Diseases 0.000 claims 3
- 208000007101 Muscle Cramp Diseases 0.000 claims 3
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 3
- 208000031481 Pathologic Constriction Diseases 0.000 claims 3
- 201000007100 Pharyngitis Diseases 0.000 claims 3
- 206010036790 Productive cough Diseases 0.000 claims 3
- 208000037656 Respiratory Sounds Diseases 0.000 claims 3
- 208000027790 Rib fracture Diseases 0.000 claims 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 3
- 208000005392 Spasm Diseases 0.000 claims 3
- 206010047700 Vomiting Diseases 0.000 claims 3
- 206010047924 Wheezing Diseases 0.000 claims 3
- 208000013116 chronic cough Diseases 0.000 claims 3
- 230000013872 defecation Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000017574 dry cough Diseases 0.000 claims 3
- 230000006870 function Effects 0.000 claims 3
- 206010022437 insomnia Diseases 0.000 claims 3
- 230000027939 micturition Effects 0.000 claims 3
- 208000024794 sputum Diseases 0.000 claims 3
- 210000003802 sputum Anatomy 0.000 claims 3
- 230000036262 stenosis Effects 0.000 claims 3
- 208000037804 stenosis Diseases 0.000 claims 3
- 206010042772 syncope Diseases 0.000 claims 3
- 210000001186 vagus nerve Anatomy 0.000 claims 3
- 230000008673 vomiting Effects 0.000 claims 3
- 206010003645 Atopy Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008685 Chondritis Diseases 0.000 claims 2
- 208000000059 Dyspnea Diseases 0.000 claims 2
- 206010013975 Dyspnoeas Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims 2
- 206010070488 Upper-airway cough syndrome Diseases 0.000 claims 2
- 239000003434 antitussive agent Substances 0.000 claims 2
- 229940124584 antitussives Drugs 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000011109 contamination Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000000613 ear canal Anatomy 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000003172 expectorant agent Substances 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 230000002650 habitual effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 230000007383 nerve stimulation Effects 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 230000000391 smoking effect Effects 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 206010010719 Conjunctival haemorrhage Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 1
- 206010038678 Respiratory depression Diseases 0.000 claims 1
- 206010038687 Respiratory distress Diseases 0.000 claims 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 claims 1
- 206010039897 Sedation Diseases 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 1
- 208000026317 Tietze syndrome Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 230000002421 anti-septic effect Effects 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 229940124581 decongestants Drugs 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 claims 1
- 230000003419 expectorant effect Effects 0.000 claims 1
- 229940066493 expectorants Drugs 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 230000000631 nonopiate Effects 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 230000001144 postural effect Effects 0.000 claims 1
- 230000000506 psychotropic effect Effects 0.000 claims 1
- 230000036280 sedation Effects 0.000 claims 1
- 230000036299 sexual function Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 150000003505 terpenes Chemical class 0.000 claims 1
- 235000007586 terpenes Nutrition 0.000 claims 1
- 229960004559 theobromine Drugs 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1111485.7A GB201111485D0 (en) | 2011-07-05 | 2011-07-05 | Drug composition and its use in therapy |
| GB1111485.7 | 2011-07-05 | ||
| PCT/GB2012/050816 WO2013004999A1 (en) | 2011-07-05 | 2012-04-13 | Drug combinations and uses in treating a coughing condition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017212821A Division JP2018048189A (ja) | 2011-07-05 | 2017-11-02 | 薬剤の組合せ、および咳嗽状態の治療における使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014518252A JP2014518252A (ja) | 2014-07-28 |
| JP2014518252A5 true JP2014518252A5 (enExample) | 2015-05-21 |
Family
ID=44512137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517915A Pending JP2014518252A (ja) | 2011-07-05 | 2012-04-13 | 薬剤の組合せ、および咳嗽状態の治療における使用 |
| JP2017212821A Pending JP2018048189A (ja) | 2011-07-05 | 2017-11-02 | 薬剤の組合せ、および咳嗽状態の治療における使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017212821A Pending JP2018048189A (ja) | 2011-07-05 | 2017-11-02 | 薬剤の組合せ、および咳嗽状態の治療における使用 |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP3251665A1 (enExample) |
| JP (2) | JP2014518252A (enExample) |
| KR (1) | KR101676454B1 (enExample) |
| CN (1) | CN103648488A (enExample) |
| AU (2) | AU2012280019B2 (enExample) |
| BR (1) | BR112014000159A2 (enExample) |
| CA (1) | CA2840793A1 (enExample) |
| GB (1) | GB201111485D0 (enExample) |
| MX (1) | MX2014000129A (enExample) |
| RU (2) | RU2016101054A (enExample) |
| WO (1) | WO2013004999A1 (enExample) |
| ZA (1) | ZA201400010B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10016437B2 (en) | 2009-06-16 | 2018-07-10 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| GB201111485D0 (en) * | 2011-07-05 | 2011-08-17 | Biocopea Ltd | Drug composition and its use in therapy |
| US9314465B2 (en) | 2009-06-16 | 2016-04-19 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| GB201014391D0 (en) * | 2010-08-27 | 2010-10-13 | Biocopea Ltd | Drug composition and its use in therapy |
| GB0910375D0 (en) | 2009-06-16 | 2009-07-29 | Biocopea Ltd | Drug composition and its use in therapy |
| US9308211B2 (en) | 2009-06-16 | 2016-04-12 | Infirst Healthcare Limited | Drug combinations and uses in treating a coughing condition |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US10149823B2 (en) | 2013-04-30 | 2018-12-11 | Otitopic Inc. | Dry powder formulations and methods of use |
| AU2015315455A1 (en) * | 2014-09-08 | 2017-04-27 | Gotham Biopharmaceuticals, Inc. | Mucolytic agents for use in tretaing pulmonary sarcoidosis |
| CN104436176A (zh) * | 2014-11-17 | 2015-03-25 | 华东理工大学 | 一种基于上呼吸道感染及肺炎用的新型生物抗菌喷雾剂 |
| AU2017432640B2 (en) | 2017-09-22 | 2023-11-30 | Aspeya US Inc. | Dry powder compositions with magnesium stearate |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| CN109793823A (zh) * | 2017-11-17 | 2019-05-24 | 中国科学院大连化学物理研究所 | 一种外用止咳平喘软膏剂及其制备方法 |
| US20200022974A1 (en) * | 2018-07-23 | 2020-01-23 | Trevi Therapeutics, Inc. | Treatment of chronic cough, breathlessness and dyspnea |
| JP2022529353A (ja) | 2019-04-17 | 2022-06-21 | コンパス パスファインダー リミテッド | 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法 |
| US20240122934A1 (en) * | 2019-10-16 | 2024-04-18 | University Of South Florida | Compositions and methods of treatment for inhibiting capillary tube regression |
| EP4084871A4 (en) * | 2019-12-31 | 2024-01-24 | The Trustees of Indiana University | RE-PURPOSING FDA-APPROVED DRUGS AS A NOVEL THERAPEUTIC WAY AGAINST CANCER VIA INHIBITION OF PRMT5 |
| MX2022008554A (es) | 2020-01-10 | 2022-08-10 | Trevi Therapeutics Inc | Metodos de administracion de nalbufina. |
| US11628165B1 (en) * | 2020-03-25 | 2023-04-18 | Helen Feng | Method of boosting immune system against viral infection |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4756911A (en) | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US20020009478A1 (en) * | 1998-08-24 | 2002-01-24 | Douglas Joseph Dobrozsi | Oral liquid mucoadhesive compositions |
| JP2002363072A (ja) * | 2001-04-03 | 2002-12-18 | Taisho Pharmaceut Co Ltd | 鎮咳用組成物 |
| JP2003081821A (ja) * | 2001-09-12 | 2003-03-19 | Taisho Pharmaceut Co Ltd | 医薬組成物 |
| JP4377564B2 (ja) * | 2002-05-02 | 2009-12-02 | ロート製薬株式会社 | 内服用組成物 |
| US6979689B2 (en) * | 2002-12-20 | 2005-12-27 | Pediamed Pharmaceuticals, Inc. | Compositions and methods for treating upper respiratory congestion |
| US20050152967A1 (en) * | 2003-03-28 | 2005-07-14 | Pfab, Lp | Dynamic variable release |
| WO2005072701A1 (en) | 2004-01-20 | 2005-08-11 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| JP4195895B2 (ja) * | 2006-04-04 | 2008-12-17 | 小林製薬株式会社 | 吐出装置を備えた容器に収容される経口投与用液体医薬製剤 |
| US20080003280A1 (en) * | 2006-06-26 | 2008-01-03 | Levine Brian M | Combination cough treatment compounds and method of treating common coughs |
| US20110008437A1 (en) | 2009-04-20 | 2011-01-13 | Altman Gregory H | Silk Fibroin Hydrogels and Uses Thereof |
| GB201014391D0 (en) * | 2010-08-27 | 2010-10-13 | Biocopea Ltd | Drug composition and its use in therapy |
| GB201111485D0 (en) * | 2011-07-05 | 2011-08-17 | Biocopea Ltd | Drug composition and its use in therapy |
| GB0919893D0 (en) * | 2009-11-13 | 2009-12-30 | Biocopea Ltd | Drug composition and its use in therapy |
| GB0921805D0 (en) * | 2009-12-14 | 2010-01-27 | Biocopea Ltd | Drug composition and its use in therapy |
| GB0919889D0 (en) * | 2009-11-13 | 2009-12-30 | Biocopea Ltd | Drug composition and its use in therapy |
| GB0921803D0 (en) * | 2009-12-14 | 2010-01-27 | Biocopea Ltd | Drug composition and its use in therapy |
| UA47594U (uk) * | 2009-09-17 | 2010-02-10 | Игорь Викторович Трутаев | Комбінований засіб для лікування та профілактики захворювань дихальних шляхів |
| JP5815226B2 (ja) * | 2009-11-30 | 2015-11-17 | 興和株式会社 | ロキソプロフェンを含有する医薬組成物 |
-
2011
- 2011-07-05 GB GBGB1111485.7A patent/GB201111485D0/en not_active Ceased
-
2012
- 2012-04-13 JP JP2014517915A patent/JP2014518252A/ja active Pending
- 2012-04-13 KR KR1020147002930A patent/KR101676454B1/ko not_active Expired - Fee Related
- 2012-04-13 WO PCT/GB2012/050816 patent/WO2013004999A1/en not_active Ceased
- 2012-04-13 MX MX2014000129A patent/MX2014000129A/es unknown
- 2012-04-13 EP EP17177202.3A patent/EP3251665A1/en not_active Withdrawn
- 2012-04-13 CN CN201280033545.1A patent/CN103648488A/zh active Pending
- 2012-04-13 RU RU2016101054A patent/RU2016101054A/ru unknown
- 2012-04-13 RU RU2014103787/15A patent/RU2014103787A/ru unknown
- 2012-04-13 BR BR112014000159-6A patent/BR112014000159A2/pt not_active IP Right Cessation
- 2012-04-13 AU AU2012280019A patent/AU2012280019B2/en not_active Ceased
- 2012-04-13 CA CA2840793A patent/CA2840793A1/en not_active Abandoned
- 2012-04-13 EP EP12716069.5A patent/EP2729136A1/en not_active Withdrawn
-
2014
- 2014-01-06 ZA ZA2014/00010A patent/ZA201400010B/en unknown
-
2016
- 2016-11-09 AU AU2016256741A patent/AU2016256741A1/en not_active Abandoned
-
2017
- 2017-11-02 JP JP2017212821A patent/JP2018048189A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014518252A5 (enExample) | ||
| RU2014103787A (ru) | Комбинации лекарственных средств и их применение в лечении состояния, сопровождающегося кашлем | |
| JP2010168404A (ja) | 睡眠時無呼吸の薬理学的処置 | |
| JP2023076465A5 (enExample) | ||
| JP2005506370A5 (enExample) | ||
| RU2005137165A (ru) | Применение соединения для лечения нарушений сна | |
| JP6753860B2 (ja) | リルゾールの舌下製剤 | |
| JP2011503045A (ja) | Ｃｒｔｈ２拮抗化合物の使用 | |
| JP2017528507A5 (enExample) | ||
| US20100204205A1 (en) | Tolerability of mirtazapine and a second active agent by using them in combination | |
| JP2009537553A5 (enExample) | ||
| JP2006507225A5 (enExample) | ||
| JP2016512817A5 (enExample) | ||
| EP2964185B1 (en) | Preparations for the treatment of sleep-related respiratory disorders | |
| JP2016507500A5 (enExample) | ||
| US20170151222A1 (en) | Snoring treatment | |
| JP2011500589A5 (enExample) | ||
| KR20150011379A (ko) | 옥시부티닌 투여를 위한 방법 및 조성물 | |
| US11744833B2 (en) | Pharmaceutical compositions and methods for treatment of insomnia | |
| JP2008516909A5 (enExample) | ||
| EP4478887A1 (en) | Novel pharmaceutical compositions and methods for treatment of insomnia | |
| JP5634529B2 (ja) | 強迫性障害（ｏｃｄ）処置用の薬剤の製造のためのアゴメラチンの使用 | |
| JP2005511632A5 (enExample) | ||
| WO2009023820A1 (en) | Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination | |
| JP2004531557A (ja) | 疼痛の処置のための４−（２−フルオロフェニル）−６−メチル−２−（１−ピペラジニル）チエノ［２，３−ｄ］ピリミジンの使用 |